source
- Novartis signs up to $3.2 billion deal with Korea's Alteogen for subcutaneous drug delivery technologyNovartis has entered an option and license agreement with Korean biotech Alteogen to use its ALT-B4 subcutaneous delivery platform, a partnership that could be worth up to $3.2 billion if all optio…
- UniQure submits FDA and UK applications for first Huntington’s disease gene therapyUniQure has filed a biologics license application (BLA) with the U.S. FDA and a separate submission with the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its experimental gene…